Stockscreener 앱 받기
1.78
2.89%
0.05
전일 마감가:
$1.73
열려 있는:
$1.75
하루 거래량:
3.22M
Relative Volume:
6.47
시가총액:
$112.96M
수익:
-
순이익/손실:
$-60.36M
주가수익비율:
-0.4051
EPS:
-4.394
순현금흐름:
$-15.05M
1주 성능:
+3.49%
1개월 성능:
-30.20%
6개월 성능:
-52.28%
1년 성능:
-44.03%
1일 변동 폭
$1.72
$1.90
1주일 범위
$1.60
$1.90
52주 변동 폭
$1.60
$6.35
Zura Bio Ltd Stock (ZURA) Company Profile
명칭
Zura Bio Ltd
전화
858-247-0520
주소
4225 EXECUTIVE SQUARE, LA JOLLA
ZURA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ZURA
Zura Bio Ltd
|
1.79 | 112.96M | 0 | -60.36M | -15.05M | -4.394 |
|
VRTX
Vertex Pharmaceuticals Inc
|
440.46 | 113.70B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.63 | 75.52B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.74 | 39.78B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.41 | 35.34B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
122.06 | 29.05B | 3.30B | -501.07M | 1.03B | -2.1146 |
Zura Bio Ltd Stock (ZURA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-04 | 개시 | Leerink Partners | Outperform |
| 2024-09-05 | 개시 | H.C. Wainwright | Neutral |
| 2024-05-03 | 개시 | Piper Sandler | Overweight |
| 2023-10-10 | 개시 | Ladenburg Thalmann | Buy |
| 2023-08-25 | 개시 | Oppenheimer | Outperform |
| 2023-06-22 | 개시 | Guggenheim | Buy |
| 2023-06-14 | 개시 | Chardan Capital Markets | Buy |
| 2023-05-24 | 개시 | Raymond James | Strong Buy |
모두보기
Zura Bio Ltd 주식(ZURA)의 최신 뉴스
Down -35.58% in 4 Weeks, Here's Why You Should You Buy the Dip in Zura Bio Limited (ZURA) - MSN
Cantor Fitzgerald Predicts Zura Bio FY2025 Earnings - MarketBeat
We Think Zura Bio (NASDAQ:ZURA) Can Afford To Drive Business Growth - Yahoo Finance
Barclays PLC Purchases 56,757 Shares of Zura Bio Limited (NASDAQ:ZURA) - Defense World
ZURA stock touches 52-week low at $1.97 amid market shifts - Investing.com Canada
Corporate Overview January 2025 Advancing Dual Pathway Biologic Candidates: Addressing Unmet Needs in Autoimmune and Inflammatory Diseases - Marketscreener.com
Barclays PLC Raises Stock Holdings in Zura Bio Limited (NASDAQ:ZURA) - Defense World
State Street Corp Increases Position in Zura Bio Limited (NASDAQ:ZURA) - Defense World
Reversal Of Fortune For Zura Bio Insiders Who Made A US$1.01m Purchase - Simply Wall St
Zura Bio’s (ZURA) Neutral Rating Reaffirmed at HC Wainwright - Defense World
Zura Bio shares outlook positive as Phase 2 TibuSURE study evaluates key SSc complications - Investing.com India
Zura Bio begins Phase 2 study for systemic sclerosis treatment By Investing.com - Investing.com South Africa
Zura Bio initiates Phase II systemic sclerosis treatment trial - Yahoo Finance
Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis - Quantisnow
17,442 Shares in Zura Bio Limited (NASDAQ:ZURA) Acquired by The Manufacturers Life Insurance Company - Defense World
Zura Bio FY2025 EPS Forecast Increased by Leerink Partnrs - Defense World
Zura Bio FY2025 EPS Forecast Boosted by Leerink Partnrs - MarketBeat
Cantor Fitzgerald Reaffirms Overweight Rating for Zura Bio (NASDAQ:ZURA) - Defense World
Zura Bio Limited (NASDAQ:ZURA) Receives $15.80 Average PT from Analysts - Defense World
Zura Bio Limited (NASDAQ:ZURA) Receives $15.80 Average Target Price from Analysts - MarketBeat
Zura Bio Limited (NASDAQ:ZURA) Short Interest Update - Defense World
Zura Bio : to Present at the Piper Sandler 36th Annual Healthcare Conference Form 8 K - Marketscreener.com
Zura Bio to Present at the Piper Sandler 36th Annual Healthcare Conference - Yahoo Finance
Zura Bio to Present at Piper Sandler Healthcare Conference, Showcasing Immunology Pipeline - StockTitan
We're Hopeful That Zura Bio (NASDAQ:ZURA) Will Use Its Cash Wisely - Simply Wall St
HC Wainwright Reaffirms “Neutral” Rating for Zura Bio (NASDAQ:ZURA) - Defense World
HC Wainwright Reaffirms "Neutral" Rating for Zura Bio (NASDAQ:ZURA) - MarketBeat
GREAT POINT PARTNERS LLC Reduces Stake in Zura Bio Ltd - GuruFocus.com
ADAR1 Capital Management, LLC Acquires New Stake in Zura Bio Ltd - GuruFocus.com
Zura Bio advances Phase 2 study for systemic sclerosis treatment - Investing.com
Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis - Yahoo Finance
HC Wainwright Has Positive Outlook for Zura Bio Q3 Earnings - MarketBeat
Guggenheim maintains Buy on Zura Bio, target steady at $15 - Investing.com India
Guggenheim maintains Buy on Zura Bio, target steady at $15 By Investing.com - Investing.com UK
Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates - BioSpace
Q3 Earnings Forecast for Zura Bio Issued By Leerink Partnrs - MarketBeat
Zura Bio (NASDAQ:ZURA) Stock Rating Upgraded by Leerink Partnrs - Defense World
Piper Sandler sets price target on Zura Bio shares, cites positive trial data - Investing.com
Leerink Partners initiates Zura Bio stock with Outperform rating, $15 target - Investing.com
Zura Bio Ltd re-elects board, ratifies auditor at AGM By Investing.com - Investing.com Australia
Zura Bio to Participate in Two Upcoming Investor Conferences in November - Yahoo Finance
Zura Bio Ltd re-elects board, ratifies auditor at AGM - Investing.com India
Zura Bio announces departure of Chief Scientific Officer By Investing.com - Investing.com Australia
Zura Bio announces departure of Chief Scientific Officer - Investing.com India
Zura Bio Ltd (ZURA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.42%
4.93%
자본화:
|
볼륨(24시간):